Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration

  • Authors:
    • Lingyun Zhang
    • Yuee Teng
    • Ye Zhang
    • Jing Liu
    • Ling Xu
    • Jinglei Qu
    • Kezuo Hou
    • Yunpeng Liu
    • Xiujuan Qu
  • View Affiliations

  • Published online on: November 16, 2011     https://doi.org/10.3892/mmr.2011.678
  • Pages: 580-584
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The receptor activator of nuclear factor κB ligand/receptor activator of nuclear factor κB (RANKL/RANK) pathway is crucial for the migration of RANK-expressing cancer cells. The ubiquitin-proteasome protein degradation pathway plays a significant role in tumor metastasis. However, the relationship between these two pathways in tumor cell migration is unclear. In the present study, we explored the effect of the proteasome inhibitor bortezomib (PS-341) on RANKL-induced MDA-MB-231 breast cancer cell migration. Transwell migration assay showed that RANKL-induced MDA-MB-231 cell migration was significantly blocked by the decoy receptor osteoprotegerin (OPG), and was also inhibited by the PI3-K inhibitor LY294002. Western blotting results showed that Akt was rapidly activated by soluble RANKL treatment. PS-341 significantly enhanced RANKL-induced MDA-MB-231 cell migration. Further study showed that the enhancement of migration by PS-341 involved upregulation of activated Akt and RANK. Our results for the first time support the theory that PS-341 treatment may be unsuitable for RANK-positive breast cancer patients.

Related Articles

Journal Cover

February 2012
Volume 5 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Liu Y and Qu X: Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration. Mol Med Rep 5: 580-584, 2012
APA
Zhang, L., Teng, Y., Zhang, Y., Liu, J., Xu, L., Qu, J. ... Qu, X. (2012). Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration. Molecular Medicine Reports, 5, 580-584. https://doi.org/10.3892/mmr.2011.678
MLA
Zhang, L., Teng, Y., Zhang, Y., Liu, J., Xu, L., Qu, J., Hou, K., Liu, Y., Qu, X."Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration". Molecular Medicine Reports 5.2 (2012): 580-584.
Chicago
Zhang, L., Teng, Y., Zhang, Y., Liu, J., Xu, L., Qu, J., Hou, K., Liu, Y., Qu, X."Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration". Molecular Medicine Reports 5, no. 2 (2012): 580-584. https://doi.org/10.3892/mmr.2011.678